8-K: AngioDynamics Reports Fiscal Year 2024 Results, Highlights Strategic Transformation

AngioDynamics announced its fiscal year 2024 results, showcasing growth in Med Tech sales and progress in its strategic transformation.

Summary

• AngioDynamics reported a 5.3% increase in pro forma net sales for fiscal year 2024, reaching $270.7 million.
• Med Tech net sales grew by 10.1% to $106.0 million, while Med Device net sales increased by 2.4% to $164.8 million.
• The company's GAAP net loss for the year was $184.3 million, or a loss per share of $4.59, which includes a $159.5 million goodwill impairment and $19.3 million related to IP litigation settlement.
• Adjusted loss per share for the year was $(0.45), compared to $(0.55) in the prior year.
• For the fourth quarter, pro forma net sales were $71.1 million, a 1.9% increase year-over-year, with Med Tech sales up 11.3% and Med Device sales down 3.8%.
• The company achieved FDA 510(k) clearance and CE Mark approval for the AlphaVac F18 System for pulmonary embolism treatment.
• AngioDynamics initiated a share repurchase program for up to $15 million of its outstanding common shares.
• The company has transitioned to a fully outsourced manufacturing model, expected to reduce expenses by approximately $15 million annually by fiscal year 2027.
• AngioDynamics has divested its Dialysis and BioSentry businesses, as well as the PICC and Midline product portfolios, and discontinued the sale of its RadioFrequency and Syntrax products.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong growth in the Med Tech segment, strategic moves to improve financial health, and the launch of a share repurchase program. However, the significant GAAP loss and continued adjusted losses temper the overall optimism.

Positives

• The Med Tech segment showed strong growth, with a 10.1% increase in net sales for the full year and 11.3% in the fourth quarter.
• The AlphaVac system received key regulatory approvals, opening up new market opportunities.
• The company has strengthened its balance sheet by eliminating all long-term debt and increasing cash reserves.
• The transition to outsourced manufacturing is expected to significantly reduce costs.
• The settlement of the IP litigation allows the company to focus on innovation and growth.
• The share repurchase program indicates confidence in the company's future prospects.

Negatives

• The company reported a significant GAAP net loss of $184.3 million for the full year, primarily due to a goodwill impairment and litigation settlement costs.
• Med Device net sales decreased by 3.8% in the fourth quarter.
• The company experienced a decrease in international net sales by 9.9% in the fourth quarter.
• Gross margin declined by 110 basis points to 53.8% for the full year.
• The company is still reporting an adjusted loss per share of $(0.45) for the full year.

Risks

• The company's future performance is subject to risks and uncertainties, including the impact of the COVID-19 pandemic, competition, and regulatory actions.
• The transition to outsourced manufacturing may present challenges and potential disruptions.
• The company's ability to achieve its financial guidance depends on successful execution of its strategic initiatives.
• The company's international sales are subject to foreign currency exchange rate fluctuations.
• The company's products are subject to market acceptance and competition.

Future Outlook

For fiscal year 2025, the company expects net sales to be in the range of $282 to $288 million, Med Tech net sales to grow by 10% to 12%, Med Device net sales to grow by 1% to 3%, gross margin to be approximately 52% to 53%, adjusted EBITDA loss of $2.5 million to $0, and adjusted loss per share in the range of $0.38 to $0.42.

Management Comments

• We capped off a transformative 2024 with a solid fourth quarter, largely driven by a second straight quarter of double-digit increases in our Med Tech business as Auryon and NanoKnife, delivered strong revenue growth, commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc.
• Over the last three years, AngioDynamics has undergone a significant transformation to position ourselves for long-term success.
• We view 2025 as an inflection point in the trajectory of our business.

Industry Context

The announcement reflects a broader trend in the medical device industry where companies are focusing on high-growth segments, streamlining operations, and improving financial health through strategic divestitures and cost-cutting measures. The focus on innovative technologies like Auryon, NanoKnife, and AlphaVac aligns with the industry's push for advanced treatment options.

Comparison to Industry Standards

• AngioDynamics' Med Tech growth of 10.1% for the year is strong compared to some established medical device companies, but it is important to note that this is from a smaller base.
• Companies like Medtronic and Boston Scientific, while having much larger revenue bases, often see growth in the low to mid single digits, making AngioDynamics' Med Tech growth notable.
• The divestiture of non-core assets is a common strategy in the industry, similar to moves by companies like Johnson & Johnson to focus on core businesses.
• The move to outsourced manufacturing is also a trend seen in the industry to improve margins, with companies like Stryker using this strategy to reduce costs.
• The settlement of the IP litigation is a positive step, as protracted legal battles can be a significant drain on resources, similar to the challenges faced by other medical device companies in the past.

Legal Proceedings

• The company reached a settlement agreement with Becton, Dickinson and C.R. Bard, ending a decade-long intellectual property litigation.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's focus on growth and profitability.
• Employees may be impacted by the transition to outsourced manufacturing.
• Customers will benefit from the company's innovative medical technology solutions.
• Suppliers may be impacted by the shift to outsourced manufacturing.
• Creditors will benefit from the company's improved financial health and elimination of long-term debt.

Next Steps

• The company will focus on the full commercial launch of the AlphaVac system for pulmonary embolism in the U.S. and CE Marked countries.
• AngioDynamics will pursue international expansion for the Auryon platform.
• The company expects to receive an expanded indication for NanoKnife in the treatment of prostate tissue by the end of calendar 2024.
• The company will continue to transition to a fully outsourced manufacturing model.
• The company will execute on its share repurchase program.

Key Dates

Keywords

AngioDynamics, Med Tech, Med Device, AlphaVac, NanoKnife, Pulmonary Embolism, Manufacturing Outsourcing, Share Repurchase, Financial Results, Medical Technology